非小细胞肺癌患者接受PD-1/PD-L1阻断治疗期间的超进展疾病
该研究纳入2014年4月至2018年11月期间接受PD-1/PD-L1抑制剂治疗的复发和/或转移性非小细胞肺癌患者263例,按肿瘤生长动力学(TGK)、肿瘤生长速率(TGR)和至治疗失败时间(TTF)三种标准评估超进展疾病(HPD)的发生率分别为20.9%、20.5%和37.3%。同时满足TGK和TGR标准的HPD与更差的无进展生存(HR 4.619;95%CI 2.868-7.440)和总生存(HR 5.079;95%CI 3.136-8.226)相关。外周血CD8+ T淋巴细胞中较低的效应/记忆亚群频率和较高的严重耗竭亚群频率与HPD及更差生存率相关。
要点
- HPD在NSCLC患者接受PD-1/PD-L1抑制剂治疗中常见,按TGK、TGR、TTF标准发生率分别为20.9%、20.5%、37.3%。
- 同时满足TGK和TGR标准的HPD与更差的无进展生存(HR 4.619;95%CI 2.868-7.440)和总生存(HR 5.079;95%CI 3.136-8.226)相关。
- 外周血CD8+ T淋巴细胞中较低的效应/记忆亚群频率和较高的严重耗竭亚群频率与HPD及更差生存率相关。
核心结论
- HPD在NSCLC患者接受PD-1/PD-L1抑制剂治疗中常见。
- 基于合理设计的分析得出的生物标志物可能成功预测HPD和更差结局,值得进一步研究HPD。
研究设计与样本
- 研究纳入2014年4月至2018年11月期间接受PD-1/PD-L1抑制剂治疗的复发和/或转移性NSCLC患者。
- 共分析263例患者,分析临床病理变量、肿瘤生长动态和治疗结局。
- HPD根据肿瘤生长动力学(TGK)、肿瘤生长速率(TGR)和至治疗失败时间(TTF)定义。
- 对外周血CD8+ T淋巴细胞进行免疫表型分析以探索HPD的潜在预测生物标志物。
主要发现
- 根据TGK、TGR和TTF标准,HPD分别见于55例(20.9%)、54例(20.5%)和98例(37.3%)患者。
- 同时满足TGK和TGR标准的HPD与更差的无进展生存相关(HR 4.619;95%CI 2.868-7.440),与更差的总生存相关(HR 5.079;95%CI 3.136-8.226),对照为不伴HPD的进展性疾病。
- 未发现HPD特异的临床病理变量。
- 在外周血CD8+ T淋巴细胞的探索性生物标志物分析中,总CD8+ T细胞中较低的效应/记忆亚群(CCR7-CD45RA- T细胞)频率和PD-1+CD8+ T细胞中较高的严重耗竭群体(TIGIT+ T细胞)频率与HPD及更差生存率相关。
关键数值与推荐
- HPD根据TGK、TGR和TTF三种标准定义。
- 同时满足TGK和TGR标准的HPD与更差的无进展生存相关(HR 4.619;95%CI 2.868-7.440)和总生存相关(HR 5.079;95%CI 3.136-8.226),对照为不伴HPD的进展性疾病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However, emerging evidence show that PD-1/PD-L1 blockade can lead to hyperprogressive disease (HPD), a flair-up of tumor growth linked to dismal prognosis. This study aimed to evaluate the incidence of HPD and identify the determinants associated with HPD in patients with NSCLC treated with PD-1/PD-L1 blockade. PATIENTS AND METHODS: We enrolled patients with recurrent and/or metastatic NSCLC treated with PD-1/PD-L1 inhibitors between April 2014 and November 2018. Clinicopathologic variables, dynamics of tumor growth, and treatment outcomes were analyzed in patients with NSCLC who received PD-1/PD-L1 blockade. HPD was defined according to tumor growth kinetics (TGK), tumor growth rate (TGR), and time to treatment failure (TTF). Immunophenotyping of peripheral blood CD8+ T lymphocytes was conducted to explore the potential predictive biomarkers of HPD. RESULTS: A total of 263 patients were analyzed. HPD was observed in 55 (20.9%), 54 (20.5%), and 98 (37.3%) patients according to the TGK, TGR, and TTF. HPD meeting both TGK and TGR criteria was associated with worse progression-free survival [hazard ratio (HR) 4.619; 95% confidence interval (CI) 2.868-7.440] and overall survival (HR, 5.079; 95% CI, 3.136-8.226) than progressive disease without HPD. There were no clinicopathologic variables specific for HPD. In the exploratory biomarker analysis with peripheral blood CD8+ T lymphocytes, a lower frequency of effector/memory subsets (CCR7-CD45RA- T cells among the total CD8+ T cells) and a higher frequency of severely exhausted populations (TIGIT+ T cells among PD-1+CD8+ T cells) were associated with HPD and inferior survival rate. CONCLUSION: HPD is common in NSCLC patients treated with PD-1/PD-L1 inhibitors. Biomarkers derived from rationally designed analysis may successfully predict HPD and worse outcomes, meriting further investigation of HPD.
引用
- Kim CG, Kim KH, Pyo KH, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019. PMID: 30977778. doi:10.1093/annonc/mdz123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。